Cai Lay Veterinary Pharmaceutical JSC (HNX:MKV)
Vietnam
· Delayed Price · Currency is VND 24,800
+1,000 (4.20%)
At close: Mar 5, 2026
HNX:MKV Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 148,869 | 107,036 | 110,906 | 119,634 | 102,410 | Upgrade
|
| Revenue Growth (YoY) | 39.08% | -3.49% | -7.30% | 16.82% | -23.90% | Upgrade
|
| Cost of Revenue | 97,203 | 71,100 | 78,674 | 86,605 | 80,112 | Upgrade
|
| Gross Profit | 51,665 | 35,937 | 32,232 | 33,029 | 22,298 | Upgrade
|
| Selling, General & Admin | 27,317 | 23,877 | 21,539 | 21,086 | 14,185 | Upgrade
|
| Operating Expenses | 27,317 | 23,877 | 21,539 | 21,086 | 14,185 | Upgrade
|
| Operating Income | 24,349 | 12,060 | 10,693 | 11,942 | 8,113 | Upgrade
|
| Interest Expense | -4,106 | -38.53 | -481.41 | -1,182 | -3,891 | Upgrade
|
| Interest & Investment Income | 886.88 | 428.6 | 285.51 | 247.49 | 1.04 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -8.44 | 9 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -2.08 | -3,245 | -2,754 | -3,507 | -1,721 | Upgrade
|
| Pretax Income | 21,127 | 9,197 | 7,752 | 7,502 | 2,502 | Upgrade
|
| Income Tax Expense | 4,226 | 1,872 | 1,550 | 1,598 | 735.25 | Upgrade
|
| Net Income | 16,901 | 7,324 | 6,201 | 5,904 | 1,767 | Upgrade
|
| Net Income to Common | 16,901 | 7,324 | 6,201 | 5,904 | 1,767 | Upgrade
|
| Net Income Growth | 130.75% | 18.11% | 5.04% | 234.10% | - | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | - | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | - | Upgrade
|
| Shares Change (YoY) | 0.01% | - | 0.02% | - | - | Upgrade
|
| EPS (Basic) | 3380.00 | 1464.86 | 1240.29 | 1181.00 | - | Upgrade
|
| EPS (Diluted) | 3380.00 | 1464.86 | 1240.00 | 1181.00 | - | Upgrade
|
| EPS Growth | 130.74% | 18.13% | 5.00% | - | - | Upgrade
|
| Free Cash Flow | 10,573 | 5,597 | 24,406 | 7,031 | 21,909 | Upgrade
|
| Free Cash Flow Per Share | 2114.58 | 1119.37 | 4881.24 | 1406.48 | - | Upgrade
|
| Gross Margin | 34.71% | 33.57% | 29.06% | 27.61% | 21.77% | Upgrade
|
| Operating Margin | 16.36% | 11.27% | 9.64% | 9.98% | 7.92% | Upgrade
|
| Profit Margin | 11.35% | 6.84% | 5.59% | 4.93% | 1.73% | Upgrade
|
| Free Cash Flow Margin | 7.10% | 5.23% | 22.01% | 5.88% | 21.39% | Upgrade
|
| EBITDA | 28,526 | 16,290 | 17,863 | 19,759 | 16,660 | Upgrade
|
| EBITDA Margin | 19.16% | 15.22% | 16.11% | 16.52% | 16.27% | Upgrade
|
| D&A For EBITDA | 4,178 | 4,231 | 7,171 | 7,816 | 8,546 | Upgrade
|
| EBIT | 24,349 | 12,060 | 10,693 | 11,942 | 8,113 | Upgrade
|
| EBIT Margin | 16.36% | 11.27% | 9.64% | 9.98% | 7.92% | Upgrade
|
| Effective Tax Rate | 20.00% | 20.36% | 20.00% | 21.30% | 29.38% | Upgrade
|
| Revenue as Reported | 148,869 | 107,036 | 110,906 | 119,634 | 102,410 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.